This $900,804 Project Grant award from the National Institute of Environmental Health Sciences (NIEHS) under the Environmental Health (CFDA 93.113) program supports the development and validation of an integrated microphysiological screening platform (MPS) with "virtual human" models to assess chemical toxicity and variability in human responses. The key objectives are to create an MPS platform that can elucidate inter-donor variabilities in mitochondrial toxicity and...
This $500,000 Project Grant from the National Science Foundation's Technology, Innovation, and Partnerships program aims to develop a novel human stem cell-based microfluidic developmental toxicology platform. The University of Michigan will receive funding from September 2022 to August 2024 to conduct technological development of a repeatable, controllable, high-throughput microfluidic system for generating three-dimensional multicellular organoid models for toxicity testing. The platform seeks...
This $157,667 Project Grant awarded by the Environmental Protection Agency (EPA) under the Science to Achieve Results (STAR) Research Program (CFDA 66.509) aims to develop a predicted reaction network using experimental and computational data. The purpose is to describe the environmental lifecycle of persistent biological transformation products (TPs) of chemicals in order to improve the chemical products manufacturing industry and understanding of how chemicals act at different stages of...
This Project Grant award from the National Institute of Environmental Health Sciences (NIEHS) under the Environmental Health (CFDA 93.113) federal grant program provides $295,734 to Litron Laboratories LTD, a for-profit biotechnology company, to develop a comprehensive hen's egg model for genotoxicity testing. The project aims to create a non-animal, metabolically-active in vitro assay that can effectively evaluate genotoxic risk in humans, addressing the pressing need for alternatives to...
This $249,943 Project Grant award from the National Institutes of Health's National Institute of Environmental Health Sciences (NIEHS) under the Environmental Health (CFDA 93.113) program supports the research and development of an adverse outcome pathway-focused mechanistic inference tool for 'omics data using semantic knowledge graphs. The key products and services to be delivered through this one-year award include: Improving statistical models to better quantify adverse outcome pathway...
The National Institute of Environmental Health Sciences (NIEHS) awarded Vala Sciences Inc. a $2,434,186 Project Grant under the Environmental Health (CFDA 93.113) federal grant program. The grant will fund the development of a suite of in vitro assays, called the DevNeurotoXAssay (DNTA), to test chemicals for potential developmental neurotoxic effects. The DNTA assays will utilize human induced pluripotent stem cell-derived neurons, glial, and support cells in 2D and 3D configurations. The...
This Project Grant award from the National Institutes of Health (NIH) under the Research Infrastructure Programs (CFDA 93.351) supports the development and optimization of a shell-free quail xenograft assay to streamline preclinical oncology drug development. The award of $270,428 to TEO Therapeutics Incorporated will be used to: 1) Refine and test a hardware product line for the quail xenograft assay, optimizing throughput and using environmentally-friendly materials; and 2) Develop and test...
This Project Grant award from the National Institute on Deafness and Other Communication Disorders (NIDCD), under the Federal Grant Program "Research Related to Deafness and Communication Disorders" (CFDA 93.173), aims to develop and validate a machine learning platform to predict the ototoxic (hearing loss-inducing) potential of pharmaceutical drugs. The award, totaling $275,737, will enable the small business Rewire Neuroscience LLC to: 1) optimize and apply their machine learning...
The National Institute of Environmental Health Sciences (NIEHS) awarded a $553,708 Project Grant under the Environmental Health (CFDA 93.113) program to the University of North Carolina at Chapel Hill (UNC-CH) on July 23, 2024. The grant will fund the development of a community-led Zebrafish Toxicology Phenotype Atlas to advance standardized data models and ontologies for annotating zebrafish toxicology exposures and their phenotypic outcomes. Key products and services to be delivered include:...
This Project Grant award from the National Institute on Drug Abuse (NIDA) under the Drug Abuse and Addiction Research Programs (CFDA 93.279) aims to develop and test a mobile health system prototype for early prediction of chemotherapy-induced peripheral neuropathy (CIPN). The $403,240 award to Newventureiq LLC will fund the development of the "Allo-Cold" mobile app, which will use a patient-reported data collection approach to quantify cold hypersensitivity as an early biomarker for...
STOPTOX: A COMPREHENSIVE IN SILICO PLATFORM FOR PREDICTING SYSTEMIC AND TOPICAL TOXICITY - THERE IS A STRONG NEED TO DEVELOP NEW ALTERNATIVE METHODS (NAMS) TO REDUCE ANIMAL TESTING OF CHEMICAL, COSMETIC, AND PHARMACEUTICAL PRODUCTS TO EVALUATE CHEMICAL TOXICITY. "6-PACK" BATTERY OF REGULATORY ASSAYS (ACUTE ORAL TOXICITY, ACUTE DERMAL TOXICITY, ACUTE INHALATION TOXICITY, SKIN IRRITATION AND CORROSION, EYE IRRITATION AND CORROSION, AND SKIN SENSITIZATION) IS A COLLECTION OF TESTS THAT CHEMICAL PRODUCTS MUST GO THROUGH TO ACHIEVE REGULATORY APPROVAL. COMPUTATIONAL APPROACHES THAT CAN ACCURATELY ESTIMATE THE RESULTS OF THE EXPERIMENTAL TESTING CAN PROVIDE A POWERFUL ALTERNATIVE TO IN VIVO INVESTIGATIONS. PREVIOUSLY, BOTH OUR GROUP AND SEVERAL OTHER GROUPS HAVE DEVELOPED MODELS FOR SOME OF THESE ENDPOINTS BUT USING LIMITED DATA OR, IN SOME CASES, LACKING RIGOR IN BOTH CURATION OF THE REPORTED DATA AND MODEL VALIDATION STRATEGIES. THIS PROJECT ADDRESSES THESE DEFICIENCIES. WE RECENTLY FORMED PREDICTIVE, LLC, TO ENABLE THE DEVELOPMENT AND DISTRIBUTION OF COMMERCIAL AND REGULATORY STRENGTH MODELS TO PREDICT IMPORTANT TOXICITY ENDPOINTS. IN THIS PHASE I STTR APPLICATION, WE INTEND TO PRODUCE RIGOROUSLY VALIDATED MODELS OF ALL "6-PACK" ASSAYS, TRANSFER THESE MODELS TO PREDICTIVE, LLC, AND INTEGRATE THESE MODELS INTO A SOFTWARE PRODUCT TERMED STOPTOX (SYSTEMIC AND TOPICAL TOXICITY) PREDICTOR. WE WILL ACHIEVE THIS OBJECTIVE BY FOCUSING ON THE FOLLOWING SPECIFIC AIMS. SPECIFIC AIM 1. DEVELOP ADVANCED MODELS FOR THE "6-PACK" BATTERY OF TESTS. WE WILL INGEST NEW DATA AND DEVELOP NEW CONSENSUS MODELS USING MULTIPLE TYPES OF DESCRIPTORS AND ADVANCED MODELING TECHNIQUES, INCLUDING DEEP LEARNING METHODS. WE WILL ALSO GENERATE A BAYESIAN MODEL APPLYING INDIVIDUAL PREDICTIONS OF EACH UNIQUE MODEL AS DESCRIPTORS, WHICH COULD ASSESS IF A COMPOUND WOULD BE ACTIVE IN ANY OF THE 6-PACK TESTS. SPECIFIC AIM 2: MODEL INTERPRETATION AND ELUCIDATION OF ADVERSE OUTCOMES PATHWAYS (AOPS.) WE WILL ENABLE PROTOCOLS AND TOOLS FOR MODEL INTERPRETATION, WHICH IS AN IMPORTANT PART OF REGULATORY DECISION SUPPORT, BOTH IN TERMS OF PF CHEMICAL FEATURES RESPONSIBLE FOR TOXICITY, AND RESPECTIVE AOPS. PREDICTIVE PROBABILITY MAPS WILL BE IMPLEMENTED AS A GRAPHICAL VISUALIZATION OF THE PREDICTED FRAGMENT CONTRIBUTION, ALLOWING THE USER TO INTERPRET THE PREDICTION AND DESIGN SAFER COMPOUNDS. IN A PARALLEL EFFORT, WE WILL WORK ON THE ISSUE OF AOPS, WHICH IS VERY IMPORTANT FOR A MECHANISTIC UNDERSTANDING OF TOXICITY MECHANISMS AND REGULATORY ACCEPTANCE OF NEW CHEMICALS. SPECIFIC AIM 3: STOPTOX PLATFORM DEVELOPMENT. PREDICTIVE, LLC, WILL IMPLEMENT ALL MODELS IN A SOFTWARE THAT WILL RUN BOTH LOCALLY STANDALONE AND ON A SECURE WEB PORTAL. TESTING WILL BE DONE BOTH INTERNALLY AND BY EXTERNAL USERS. PREDICTIONS FOR INDIVIDUAL MODELS, THE SMART-CONSENSUS BAYESIAN MODELS, AS WELL AS PREDICTED FRAGMENT CONTRIBUTIONS, WILL BE DISPLAYED ON THE SCREEN AND THE USER WILL BE ABLE TO DOWNLOAD A REPORT WITH THE RESULTS AND A SUMMARY OF CHARACTERISTICS OF THE MODELS AND INSTRUCTIONS TO HELP INTERPRET THE RESULTS. THE ULTIMATE OBJECTIVE OF THIS PROPOSAL IS TO LEVERAGE PUBLIC DATA KNOWLEDGE ON COMPOUNDS TESTED IN "6-PACK" REGULATORY ASSAYS BY CREATING A SOFTWARE PLATFORM (STOPTOX) TO BE COMMERCIALIZED AS A SERVICE OR LICENSED TO COMMERCIAL USERS.